Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2
Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against seve...
Saved in:
Published in | bioRxiv |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article Paper |
Language | English |
Published |
United States
Cold Spring Harbor Laboratory Press
28.11.2022
Cold Spring Harbor Laboratory |
Edition | 1.1 |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcγR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcγRs, especially murine FcγR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcγR III. Our passive and active immunization studies in mice suggest that Fc-FcγR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains. |
---|---|
AbstractList | Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcgR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcgRs, especially murine FcgR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcgR III. Our passive and active immunization studies in mice suggest that Fc-FcgR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains.Competing Interest StatementM.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and Moderna. R.S.B is a member of the Scientific Advisory Board of VaxArt and Adagio, has consulted for Takeda, and received unrelated funding from J&J and Pfizer. G.A. is a founder/equity holder in Seroymx Systems and Leyden Labs and has served as a scientific advisor for Sanofi Vaccines. G.A. has collaborative agreements with GlaxoSmithKline, Merck, Abbvie, Sanofi, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria. D.K.E. and G.A. are employees and shareholder in Moderna, Inc. All other authors declare no conflicts of interest. Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcγR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcγRs, especially murine FcγR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcγR III. Our passive and active immunization studies in mice suggest that Fc-FcγR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains.Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcγR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcγRs, especially murine FcγR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcγR III. Our passive and active immunization studies in mice suggest that Fc-FcγR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains. Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines against the ancestral Wuhan-1 virus. Nonetheless, these vaccines, including mRNA-1273 and BNT162b2, retained their ability to protect against severe disease and death, suggesting that other aspects of immunity control infection in the lung. Although vaccine-elicited antibodies can bind Fc gamma receptors (FcγRs) and mediate effector functions against SARS-CoV-2 variants, and this property correlates with improved clinical COVID-19 outcome, a causal relationship between Fc effector functions and vaccine-mediated protection against infection has not been established. Here, using passive and active immunization approaches in wild-type and Fc-gamma receptor (FcγR) KO mice, we determined the requirement for Fc effector functions to protect against SARS-CoV-2 infection. The antiviral activity of passively transferred immune serum was lost against multiple SARS-CoV-2 strains in mice lacking expression of activating FcγRs, especially murine FcγR III (CD16), or depleted of alveolar macrophages. After immunization with the preclinical mRNA-1273 vaccine, protection against Omicron BA.5 infection in the respiratory tract also was lost in mice lacking FcγR III. Our passive and active immunization studies in mice suggest that Fc-FcγR engagement and alveolar macrophages are required for vaccine-induced antibody-mediated protection against infection by antigenically changed SARS-CoV-2 variants, including Omicron strains. |
Author | Whitener, Bradley M Baric, Ralph S Alter, Galit Liu, Meizi Chicz, Taras M Mackin, Samantha R Edwards, Darin K McNamara, Ryan P Diamond, Michael S Karl, Courtney E Desai, Pritesh |
Author_xml | – sequence: 1 givenname: Samantha R surname: Mackin fullname: Mackin, Samantha R organization: Department of Pathology & Immunology, Washington University School of Medicine, St. Louis, MO – sequence: 2 givenname: Pritesh surname: Desai fullname: Desai, Pritesh organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO – sequence: 3 givenname: Bradley M surname: Whitener fullname: Whitener, Bradley M organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO – sequence: 4 givenname: Courtney E surname: Karl fullname: Karl, Courtney E organization: Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO – sequence: 5 givenname: Meizi surname: Liu fullname: Liu, Meizi organization: Department of Medicine, Washington University School of Medicine, St. Louis, MO – sequence: 6 givenname: Ralph S surname: Baric fullname: Baric, Ralph S organization: Department of Epidemiology, University of North Carolina, Chapel Hill, NC – sequence: 7 givenname: Darin K surname: Edwards fullname: Edwards, Darin K organization: Moderna, Inc., Cambridge MA – sequence: 8 givenname: Taras M surname: Chicz fullname: Chicz, Taras M organization: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA – sequence: 9 givenname: Ryan P surname: McNamara fullname: McNamara, Ryan P organization: Ragon Institute of MGH, MIT and Harvard, Cambridge, MA – sequence: 10 givenname: Galit surname: Alter fullname: Alter, Galit organization: Andrew M. and Jane M. Bursky the Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine, St. Louis, MO – sequence: 11 givenname: Michael S surname: Diamond fullname: Diamond, Michael S organization: Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine, St. Louis, MO |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36482975$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkUtOHDEQhq2ICAjhANlElrLJpgeX3e52L9EohEhIkSDJtuVHGRnN2IPdjZhD5DS5R86EgUmIsqrXV3-pqt6QvZgiEvIO2AKAwQlnnFdvwfuFBAXQvyKHvBt4oziTe__4B-S4lBvGGB86EH27Tw5E1yo-9PKQ_Dyzv3_RjBY3U8qNww1Gh3GiOk7BJLel6D3aWqN-jnYKKRaqM9aW2zlkdNTX0p22NkSkm5wmfIKovtYhlomG6HcZs30SvcYYbO3IoUaFJk-vTi-vmmX60fC35LXXq4LHO3tEvp99-rY8by6-fv6yPL1oDAfZN06hUI4L5TvhgStsuXFaMuW9gQEtuM7pVqJWcjBtr5BrK40X1qqeCQviiHx81jUh5ftwN25yWOu8HR-POgKMvB-fj_qC1t1uZyzTuA7F4mqlI6a5VFIKAUx0XUU__IfepDnHukilWgDeDu2j4PsdNZs1ur-j__xEPABKKJFo |
ContentType | Journal Article Paper |
Copyright | 2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. 2022, Posted by Cold Spring Harbor Laboratory |
Copyright_xml | – notice: 2022. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (“the License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: 2022, Posted by Cold Spring Harbor Laboratory |
DBID | NPM 8FE 8FH ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU COVID DWQXO GNUQQ HCIFZ LK8 M7P PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 FX. |
DOI | 10.1101/2022.11.27.518117 |
DatabaseName | PubMed ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection (ProQuest) ProQuest Central Natural Science Collection ProQuest One Community College Coronavirus Research Database ProQuest Central ProQuest Central Student ProQuest SciTech Premium Collection Biological Sciences Biological Science Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic bioRxiv |
DatabaseTitle | PubMed Publicly Available Content Database ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Biological Science Collection ProQuest Central Essentials ProQuest One Academic Eastern Edition Coronavirus Research Database ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection Biological Science Database ProQuest SciTech Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest One Academic UKI Edition Natural Science Collection ProQuest Central Korea Biological Science Collection ProQuest Central (New) ProQuest One Academic ProQuest One Academic (New) MEDLINE - Academic |
DatabaseTitleList | Publicly Available Content Database MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: FX. name: bioRxiv url: https://www.biorxiv.org/ sourceTypes: Open Access Repository – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Biology |
EISSN | 2692-8205 |
Edition | 1.1 |
ExternalDocumentID | 2022.11.27.518117v1 36482975 |
Genre | Preprint Working Paper/Pre-Print |
GrantInformation_xml | – fundername: NIAID NIH HHS grantid: R01 AI157155 – fundername: NIAID NIH HHS grantid: R01 AI110700 – fundername: NIAID NIH HHS grantid: 75N93019C00051 – fundername: NIAID NIH HHS grantid: 75N93021C00014 |
GroupedDBID | 8FE 8FH AFKRA ALMA_UNASSIGNED_HOLDINGS BBNVY BENPR BHPHI HCIFZ LK8 M7P NPM NQS PHGZT PIMPY PROAC RHI ABUWG AZQEC CCPQU COVID DWQXO GNUQQ PHGZM PKEHL PQEST PQGLB PQQKQ PQUKI PRINS 7X8 FX. |
ID | FETCH-LOGICAL-b2157-d8e38d238f63f128e42bda508ffb19ec1d6da45ea859b478e2ac5bf3cc8703c13 |
IEDL.DBID | FX. |
ISSN | 2692-8205 |
IngestDate | Tue Jan 07 18:53:04 EST 2025 Mon Jul 21 09:19:06 EDT 2025 Fri Jul 25 09:16:44 EDT 2025 Thu Apr 03 07:08:45 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | false |
Language | English |
License | This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0 |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-b2157-d8e38d238f63f128e42bda508ffb19ec1d6da45ea859b478e2ac5bf3cc8703c13 |
Notes | SourceType-Working Papers-1 ObjectType-Working Paper/Pre-Print-1 content type line 50 ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 Competing Interest Statement: M.S.D. is a consultant for Inbios, Vir Biotechnology, Senda Biosciences, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent BioSolutions, and Moderna. R.S.B is a member of the Scientific Advisory Board of VaxArt and Adagio, has consulted for Takeda, and received unrelated funding from J&J and Pfizer. G.A. is a founder/equity holder in Seroymx Systems and Leyden Labs and has served as a scientific advisor for Sanofi Vaccines. G.A. has collaborative agreements with GlaxoSmithKline, Merck, Abbvie, Sanofi, Medicago, BioNtech, Moderna, BMS, Novavax, SK Biosciences, Gilead, and Sanaria. D.K.E. and G.A. are employees and shareholder in Moderna, Inc. All other authors declare no conflicts of interest. |
ORCID | 0000-0002-8791-3165 |
OpenAccessLink | https://www.biorxiv.org/content/10.1101/2022.11.27.518117 |
PMID | 36482975 |
PQID | 2741124947 |
PQPubID | 2050091 |
PageCount | 42 |
ParticipantIDs | biorxiv_primary_2022_11_27_518117 proquest_miscellaneous_2753310366 proquest_journals_2741124947 pubmed_primary_36482975 |
PublicationCentury | 2000 |
PublicationDate | 20221128 |
PublicationDateYYYYMMDD | 2022-11-28 |
PublicationDate_xml | – month: 11 year: 2022 text: 20221128 day: 28 |
PublicationDecade | 2020 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: Cold Spring Harbor |
PublicationTitle | bioRxiv |
PublicationTitleAlternate | bioRxiv |
PublicationYear | 2022 |
Publisher | Cold Spring Harbor Laboratory Press Cold Spring Harbor Laboratory |
Publisher_xml | – name: Cold Spring Harbor Laboratory Press – name: Cold Spring Harbor Laboratory |
References | 37012355 - Nat Microbiol. 2023 Apr;8(4):569-580. doi: 10.1038/s41564-023-01359-1 Scheaffer (2022.11.27.518117v1.33) 2022 Goldblatt, Alter, Crotty, Plotkin (2022.11.27.518117v1.57) 2022; 310 Wang (2022.11.27.518117v1.38) 2022; 219 Heyman (2022.11.27.518117v1.46) 2014; 382 Gu (2022.11.27.518117v1.28) 2020; 369 Tarke (2022.11.27.518117v1.17) 2022; 185 Elliott (2022.11.27.518117v1.11) 2022; 375 Cameroni (2022.11.27.518117v1.14) 2022; 602 Brasu (2022.11.27.518117v1.18) 2022; 23 Kaplonek (2022.11.27.518117v1.39) 2022; 14 Brown (2022.11.27.518117v1.76) 2012; 386 Stadlbauer (2022.11.27.518117v1.72) 2020; 57 Botto (2022.11.27.518117v1.65) 1998; 19 Bournazos, DiLillo, Ravetch (2022.11.27.518117v1.52) 2014; 382 Laidlaw (2022.11.27.518117v1.35) 2013; 9 Nelson (2022.11.27.518117v1.66) 2020; 6 Beaudoin-Bussières (2022.11.27.518117v1.43) 2022; 38 Nimmerjahn (2022.11.27.518117v1.53) 2010; 107 Cobb (2022.11.27.518117v1.26) 2022; 3 Ioan-Facsinay (2022.11.27.518117v1.64) 2002; 16 Ackerman, Barouch, Alter (2022.11.27.518117v1.24) 2017; 275 Ravetch, Bolland (2022.11.27.518117v1.51) 2001; 19 Case (2022.11.27.518117v1.20) 2022; 13 Yamin (2022.11.27.518117v1.44) 2021; 599 Davis-Gardner (2022.11.27.518117v1.49) 2022 Chen (2022.11.27.518117v1.62) 2021 Pincetic (2022.11.27.518117v1.50) 2014; 15 Halfmann (2022.11.27.518117v1.54) 2022 Winkler (2022.11.27.518117v1.27) 2021; Jvi0151121 Richardson, Moore (2022.11.27.518117v1.23) 2021; 25 Chong (2022.11.27.518117v1.34) 2022; 39 Zhu (2022.11.27.518117v1.16) 2022; 20 Bournazos, Gupta, Ravetch (2022.11.27.518117v1.58) 2020; 20 Hassett (2022.11.27.518117v1.68) 2019; 15 Ying (2022.11.27.518117v1.30) 2021; eabm3302 Wang (2022.11.27.518117v1.12) 2022; 608 Dinnon (2022.11.27.518117v1.25) 2020; 586 Bates (2022.11.27.518117v1.3) 2021; 12 VanBlargan (2022.11.27.518117v1.73) 2021 Hederman (2022.11.27.518117v1.7) 2022 Chalkias (2022.11.27.518117v1.8) 2022; 387 Richardson (2022.11.27.518117v1.22) 2022; 30 Winkler (2022.11.27.518117v1.41) 2021; 184 Zohar (2022.11.27.518117v1.19) 2020; 183 Corbett (2022.11.27.518117v1.67) 2020; 586 Misharin, Morales-Nebreda, Mutlu, Budinger, Perlman (2022.11.27.518117v1.59) 2013; 49 Krause (2022.11.27.518117v1.1) 2021; 385 Li (2022.11.27.518117v1.32) 2022; 23 Brown (2022.11.27.518117v1.75) 2017; 443 Grunst, Uchil (2022.11.27.518117v1.15) 2022; 3 Zhuang (2022.11.27.518117v1.31) 2021; 218 Cao (2022.11.27.518117v1.13) 2021 Hassan (2022.11.27.518117v1.70) 2021 Khoury (2022.11.27.518117v1.4) 2021; 27 Case, Bailey, Kim, Chen, Diamond (2022.11.27.518117v1.74) 2020; 548 Zang (2022.11.27.518117v1.61) 2020; 5 Kaplonek (2022.11.27.518117v1.6) 2022; 55 Amanat, Krammer (2022.11.27.518117v1.2) 2020; 52 Amanat (2022.11.27.518117v1.71) 2021; 184 Ying (2022.11.27.518117v1.29) 2022; 185 Chemaitelly (2022.11.27.518117v1.37) 2021; 27 Fransen (2022.11.27.518117v1.48) 2018; 200 Sefik (2022.11.27.518117v1.56) 2022; 606 Cromer (2022.11.27.518117v1.5) 2022; 75 Bates (2022.11.27.518117v1.21) 2022; 41 Schäfer (2022.11.27.518117v1.42) 2021; 218 Bowman (2022.11.27.518117v1.40) 2022; 13 Junqueira (2022.11.27.518117v1.55) 2022; 606 Roy (2022.11.27.518117v1.69) 2011; 13 Mades (2022.11.27.518117v1.45) 2021; 11 Chen (2022.11.27.518117v1.63) 2021 Andrews (2022.11.27.518117v1.10) 2022 Accorsi (2022.11.27.518117v1.36) 2022; 327 Schyns, Bureau, Marichal (2022.11.27.518117v1.60) 2018; 2018 Cele (2022.11.27.518117v1.9) 2022; 602 Hamano, Arase, Saisho, Saito (2022.11.27.518117v1.47) 2000; 164 |
References_xml | – reference: 37012355 - Nat Microbiol. 2023 Apr;8(4):569-580. doi: 10.1038/s41564-023-01359-1 – volume: 6 start-page: eaaz6893 year: 2020 ident: 2022.11.27.518117v1.66 article-title: Impact of mRNA chemistry and manufacturing process on innate immune activation publication-title: Science advances – volume: 12 start-page: 5135 year: 2021 ident: 2022.11.27.518117v1.3 article-title: Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum publication-title: Nat Commun – volume: 608 start-page: 603 year: 2022 end-page: 608 ident: 2022.11.27.518117v1.12 article-title: Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5 publication-title: Nature – volume: 375 start-page: 1406 year: 2022 end-page: 1411 ident: 2022.11.27.518117v1.11 article-title: Rapid increase in Omicron infections in England during December 2021: REACT-1 study publication-title: Science – volume: 275 start-page: 262 year: 2017 end-page: 270 ident: 2022.11.27.518117v1.24 article-title: Systems serology for evaluation of HIV vaccine trials publication-title: Immunol Rev – volume: 219 year: 2022 ident: 2022.11.27.518117v1.38 article-title: Memory B cell responses to Omicron subvariants after SARS-CoV-2 mRNA breakthrough infection in humans publication-title: J Exp Med – volume: 382 start-page: 237 year: 2014 end-page: 248 ident: 2022.11.27.518117v1.52 article-title: humanized mice to study FcγR function publication-title: Curr Top Microbiol Immunol – volume: 369 start-page: 1603 year: 2020 end-page: 1607 ident: 2022.11.27.518117v1.28 article-title: Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy publication-title: Science – volume: 23 start-page: 543 year: 2022 end-page: 555 ident: 2022.11.27.518117v1.32 article-title: Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine publication-title: Nat Immunol – volume: 27 start-page: 1614 year: 2021 end-page: 1621 ident: 2022.11.27.518117v1.37 article-title: mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar publication-title: Nat Med – volume: 386 start-page: 117 year: 2012 end-page: 123 ident: 2022.11.27.518117v1.76 article-title: High-throughput, multiplexed IgG subclassing of antigen-specific antibodies from clinical samples publication-title: J Immunol Methods – volume: 9 start-page: e1003207 year: 2013 ident: 2022.11.27.518117v1.35 article-title: Cooperativity between CD8+ T cells, non-neutralizing antibodies, and alveolar macrophages is important for heterosubtypic influenza virus immunity publication-title: PLoS Pathog – year: 2021 ident: 2022.11.27.518117v1.13 article-title: Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies publication-title: Nature – year: 2021 ident: 2022.11.27.518117v1.73 article-title: A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope publication-title: Immunity – volume: 55 start-page: 355 year: 2022 end-page: 365 ident: 2022.11.27.518117v1.6 article-title: mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern publication-title: Immunity – year: 2022 ident: 2022.11.27.518117v1.10 article-title: Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant publication-title: N Engl J Med – volume: 185 start-page: 1572 year: 2022 end-page: 1587 ident: 2022.11.27.518117v1.29 article-title: Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice publication-title: Cell – volume: 183 start-page: 1508 year: 2020 end-page: 1519 ident: 2022.11.27.518117v1.19 article-title: Compromised Humoral Functional Evolution Tracks with SARS-CoV-2 Mortality publication-title: Cell – volume: 327 start-page: 639 year: 2022 end-page: 651 ident: 2022.11.27.518117v1.36 article-title: Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants publication-title: Jama – volume: 599 start-page: 465 year: 2021 end-page: 470 ident: 2022.11.27.518117v1.44 article-title: Fc-engineered antibody therapeutics with improved anti-SARS-CoV-2 efficacy publication-title: Nature – volume: 75 start-page: e878 year: 2022 end-page: e879 ident: 2022.11.27.518117v1.5 article-title: Relating In Vitro Neutralization Level and Protection in the CVnCoV (CUREVAC) Trial publication-title: Clin Infect Dis – volume: 11 start-page: 24448 year: 2021 ident: 2022.11.27.518117v1.45 article-title: Detection of persistent SARS-CoV-2 IgG antibodies in oral mucosal fluid and upper respiratory tract specimens following COVID-19 mRNA vaccination publication-title: Sci Rep – volume: 20 start-page: 633 year: 2020 end-page: 643 ident: 2022.11.27.518117v1.58 article-title: The role of IgG Fc receptors in antibody-dependent enhancement publication-title: Nat Rev Immunol – volume: 184 start-page: 3936 year: 2021 end-page: 3948 ident: 2022.11.27.518117v1.71 article-title: SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2 publication-title: Cell – year: 2022 ident: 2022.11.27.518117v1.7 article-title: SARS-CoV-2 mRNA vaccination elicits broad and potent Fc effector functions to VOCs in vulnerable populations publication-title: medRxiv: the preprint server for health sciences – volume: 3 start-page: 188 year: 2022 end-page: 203 ident: 2022.11.27.518117v1.26 article-title: A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaques publication-title: Med (New York, N.Y.) – volume: Jvi0151121 year: 2021 ident: 2022.11.27.518117v1.27 article-title: SARS-CoV-2 causes lung infection without severe disease in human ACE2 knock-in mice publication-title: J Virol – volume: 52 start-page: 583 year: 2020 end-page: 589 ident: 2022.11.27.518117v1.2 article-title: SARS-CoV-2 Vaccines: Status Report publication-title: Immunity – volume: 164 start-page: 6113 year: 2000 end-page: 6119 ident: 2022.11.27.518117v1.47 article-title: Immune complex and Fc receptor-mediated augmentation of antigen presentation for in vivo Th cell responses publication-title: J Immunol – volume: 49 start-page: 503 year: 2013 end-page: 510 ident: 2022.11.27.518117v1.59 article-title: Flow cytometric analysis of macrophages and dendritic cell subsets in the mouse lung publication-title: American journal of respiratory cell and molecular biology – year: 2022 ident: 2022.11.27.518117v1.33 article-title: Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice publication-title: Nat Med – year: 2022 ident: 2022.11.27.518117v1.49 article-title: mRNA bivalent booster enhances neutralization against BA.2.75.2 and BQ.1.1 publication-title: bioRxiv – volume: 57 start-page: e100 year: 2020 ident: 2022.11.27.518117v1.72 article-title: SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup publication-title: Curr Protoc Microbiol – volume: 16 start-page: 391 year: 2002 end-page: 402 ident: 2022.11.27.518117v1.64 article-title: FcgammaRI (CD64) contributes substantially to severity of arthritis, hypersensitivity responses, and protection from bacterial infection publication-title: Immunity – volume: eabm3302 year: 2021 ident: 2022.11.27.518117v1.30 article-title: Protective activity of mRNA vaccines against ancestral and variant SARS-CoV-2 strains publication-title: Sci Transl Med – volume: 13 start-page: e0164722 year: 2022 ident: 2022.11.27.518117v1.40 article-title: Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity publication-title: mBio – volume: 387 start-page: 1279 year: 2022 end-page: 1291 ident: 2022.11.27.518117v1.8 article-title: A Bivalent Omicron-Containing Booster Vaccine against Covid-19 publication-title: N Engl J Med – volume: 39 start-page: 110799 year: 2022 ident: 2022.11.27.518117v1.34 article-title: Nasally delivered interferon-λ protects mice against infection by SARS-CoV-2 variants including Omicron publication-title: Cell Rep – volume: 200 start-page: 2615 year: 2018 end-page: 2626 ident: 2022.11.27.518117v1.48 article-title: A Restricted Role for FcγR in the Regulation of Adaptive Immunity publication-title: J Immunol – volume: 27 start-page: 1205 year: 2021 end-page: 1211 ident: 2022.11.27.518117v1.4 article-title: Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection publication-title: Nat Med – volume: 19 start-page: 56 year: 1998 end-page: 59 ident: 2022.11.27.518117v1.65 article-title: Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies publication-title: Nat Genet – volume: 19 start-page: 275 year: 2001 end-page: 290 ident: 2022.11.27.518117v1.51 article-title: IgG Fc receptors publication-title: Annu Rev Immunol – volume: 14 start-page: eabm2311 year: 2022 ident: 2022.11.27.518117v1.39 article-title: mRNA-1273 and BNT162b2 COVID-19 vaccines elicit antibodies with differences in Fc-mediated effector functions publication-title: Sci Transl Med – volume: 13 start-page: 17 year: 2011 end-page: 25 ident: 2022.11.27.518117v1.69 article-title: Creation of a panel of vectors based on ape adenovirus isolates publication-title: J Gene Med – year: 2022 ident: 2022.11.27.518117v1.54 article-title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters publication-title: Nature – volume: 443 start-page: 33 year: 2017 end-page: 44 ident: 2022.11.27.518117v1.75 article-title: Multiplexed Fc array for evaluation of antigen-specific antibody effector profiles publication-title: J Immunol Methods – volume: 185 start-page: 847 year: 2022 end-page: 859 ident: 2022.11.27.518117v1.17 article-title: SARS-CoV-2 vaccination induces immunological T cell memory able to cross-recognize variants from Alpha to Omicron publication-title: Cell – volume: 218 year: 2021 ident: 2022.11.27.518117v1.42 article-title: Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo publication-title: J Exp Med – volume: 13 start-page: 3824 year: 2022 ident: 2022.11.27.518117v1.20 article-title: Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains publication-title: Nat Commun – volume: 184 start-page: 1804 year: 2021 end-page: 1820 ident: 2022.11.27.518117v1.41 article-title: Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection publication-title: Cell – volume: 602 start-page: 664 year: 2022 end-page: 667 ident: 2022.11.27.518117v1.14 article-title: Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift publication-title: Nature – volume: 586 start-page: 560 year: 2020 end-page: 566 ident: 2022.11.27.518117v1.25 article-title: A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures publication-title: Nature – volume: 15 start-page: 707 year: 2014 end-page: 716 ident: 2022.11.27.518117v1.50 article-title: Type I and type II Fc receptors regulate innate and adaptive immunity publication-title: Nat Immunol – year: 2021 ident: 2022.11.27.518117v1.63 article-title: In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains publication-title: Nature – volume: 3 start-page: 100540 year: 2022 ident: 2022.11.27.518117v1.15 article-title: Fc effector cross-reactivity: A hidden arsenal against SARS-CoV-2’s evasive maneuvering publication-title: Cell reports. Medicine – volume: 25 start-page: 467 year: 2021 end-page: 477 ident: 2022.11.27.518117v1.23 article-title: Targeting Fc effector function in vaccine design publication-title: Expert Opin Ther Targets – volume: 606 start-page: 576 year: 2022 end-page: 584 ident: 2022.11.27.518117v1.55 article-title: FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation publication-title: Nature – volume: 2018 start-page: 5160794 year: 2018 ident: 2022.11.27.518117v1.60 article-title: Lung Interstitial Macrophages: Past, Present, and Future publication-title: J Immunol Res – volume: 602 start-page: 654 year: 2022 end-page: 656 ident: 2022.11.27.518117v1.9 article-title: Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization publication-title: Nature – volume: 38 start-page: 110368 year: 2022 ident: 2022.11.27.518117v1.43 article-title: A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection publication-title: Cell Rep – volume: 218 year: 2021 ident: 2022.11.27.518117v1.31 article-title: Mapping and role of T cell response in SARS-CoV-2-infected mice publication-title: J Exp Med – volume: 41 start-page: 111544 year: 2022 ident: 2022.11.27.518117v1.21 article-title: BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age publication-title: Cell Rep – year: 2021 ident: 2022.11.27.518117v1.62 article-title: Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies publication-title: Nat Med – year: 2021 ident: 2022.11.27.518117v1.70 article-title: A single intranasal dose of chimpanzee adenovirus-vectored vaccine protects against SARS-CoV-2 infection in rhesus macaques publication-title: Cell Reports Medicine – volume: 548 start-page: 39 year: 2020 end-page: 48 ident: 2022.11.27.518117v1.74 article-title: Growth, detection, quantification, and inactivation of SARS-CoV-2 publication-title: Virology – volume: 107 start-page: 19396 year: 2010 end-page: 19401 ident: 2022.11.27.518117v1.53 article-title: FcyRIV deletion reveals its central role for IgG2a and IgG2b activity in vivo publication-title: Proc Natl Acad Sci U S A – volume: 586 start-page: 567 year: 2020 end-page: 571 ident: 2022.11.27.518117v1.67 article-title: SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness publication-title: Nature – volume: 30 start-page: 880 year: 2022 end-page: 886 ident: 2022.11.27.518117v1.22 article-title: SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals publication-title: Cell Host Microbe – volume: 385 start-page: 179 year: 2021 end-page: 186 ident: 2022.11.27.518117v1.1 article-title: SARS-CoV-2 Variants and Vaccines publication-title: N Engl J Med – volume: 5 year: 2020 ident: 2022.11.27.518117v1.61 article-title: TMPRSS2 and TMPRSS4 promote SARS-CoV-2 infection of human small intestinal enterocytes publication-title: Sci Immunol – volume: 20 start-page: e3001609 year: 2022 ident: 2022.11.27.518117v1.16 article-title: Defining the determinants of protection against SARS-CoV-2 infection and viral control in a dose-down Ad26.CoV2.S vaccine study in nonhuman primates publication-title: PLoS Biol – volume: 606 start-page: 585 year: 2022 end-page: 593 ident: 2022.11.27.518117v1.56 article-title: Inflammasome activation in infected macrophages drives COVID-19 pathology publication-title: Nature – volume: 310 start-page: 6 year: 2022 end-page: 26 ident: 2022.11.27.518117v1.57 article-title: Correlates of protection against SARS-CoV-2 infection and COVID-19 disease publication-title: Immunol Rev – volume: 23 start-page: 1445 year: 2022 end-page: 1456 ident: 2022.11.27.518117v1.18 article-title: Memory CD8(+) T cell diversity and B cell responses correlate with protection against SARS-CoV-2 following mRNA vaccination publication-title: Nat Immunol – volume: 15 start-page: 1 year: 2019 end-page: 11 ident: 2022.11.27.518117v1.68 article-title: Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines publication-title: Molecular therapy. Nucleic acids – volume: 382 start-page: 201 year: 2014 end-page: 219 ident: 2022.11.27.518117v1.46 article-title: Antibodies as natural adjuvants publication-title: Curr Top Microbiol Immunol |
SSID | ssj0002961374 |
Score | 1.8173113 |
SecondaryResourceType | preprint |
Snippet | Emerging SARS-CoV-2 variants with antigenic changes in the spike protein are neutralized less efficiently by serum antibodies elicited by legacy vaccines... |
SourceID | biorxiv proquest pubmed |
SourceType | Open Access Repository Aggregation Database Index Database |
SubjectTerms | Alveoli Antibodies Antigenic variants Antiviral activity Biotechnology CD16 antigen COVID-19 Fc receptors Immune serum Immunization Infections Macrophages Microbiology mRNA Receptor mechanisms Respiratory tract diseases Severe acute respiratory syndrome coronavirus 2 Spike protein Strains (organisms) Vaccines |
SummonAdditionalLinks | – databaseName: ProQuest Central dbid: BENPR link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LTtww0KKskHprS2lpaWUkrobGTmLnVLWIFUICISiIW-THGOVAss0uqPsZ_ePOJN7lVG6R_IrG8_S8GDsI1GdD-SikpqebUoGoLGjhAyKPis5VgbKRzy_K05v87K64Sw9u8xRWueKJA6MOnac38iMqs0KNknP9ffZbUNco8q6mFhqv2ARZsEHja_Lz5OLyav3KIisUV0MpZllWSPryW5Fcm4iKZPhL_DqU-rDIKOMSlWDXdP2f5un_CucgeKZv2OTSzqB_yzagfce2xs6Ry232d-rFvX14sBw5FszQcBardrYLjsBqXBeWfAzW6HpO0mtAMG57wCUU_guBo8LKn6wn3zpPBRtwErf3tkGtka8CtVrulsOmiGyNxxWItO1izrvIr39cXYvj7lbI9-xmevLr-FSk7grCoZjXIhhQJqDEjqWKCDzIpQsW9bUYXVaBz0IZbF6ANUXlcm1AWl-4qLxHElc-Uztss-1a-Mi4LZWyGhTgEF63NgVuHCtvXNDGqnKX7Sew1rOxhkZNoEfro5a6HkG_y_ZWAK8TGc3r50vHLdbDSADk1bAtdI80BzXWDAUxHvNhvKj1KarMh9ThTy9v_pm9pv-hFENp9tjmon-EL6hrLNzXhFD_AFUW0zE priority: 102 providerName: ProQuest |
Title | Fcγ receptor-dependent antibody effector functions are required for vaccine protection against infection by antigenic variants of SARS-CoV-2 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/36482975 https://www.proquest.com/docview/2741124947 https://www.proquest.com/docview/2753310366 https://www.biorxiv.org/content/10.1101/2022.11.27.518117 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1bS-wwEA7qIvjm5ejxSoTzmuU0aZv2UcVFBEW8HPat5DI59KVd6iruj_DX-D_8Tc603cUHBd9KkzRlMsk3yczkY-yPJ54N5YKQmo5uUgUiN6CF86g8Klibe8pGvrpOLx7iy3Ey_kT1RWGVtqybl_K59eNTwDauvt3k_hvRXl3i01DqYRJRkuQyG6BKxcTaMBoPF8crMkec0nHvx_yyJVq8fU_fW5ctyozW2eDGTKDZYEtQbbLVjiZytsVeR-79jePSBBPcIYs5b-2Uo1RKW_sZ76Iy6oYTTLWaxE0D2ITifMFztEz5s3HkROf9zQxYiZv_pkTzkM8jsipuZ-1HUatKhy1QO6vpI68Dvzu5vRNn9T8hf7GH0fn92YXoaRSERTzXwmegMo_QHFIVEI4gltYbNMxCsFEOLvKpN3ECJktyG-sMpHGJDco5nMvKRWqbrVR1Bb8ZN6lSRoMCLMJx1VmCHw65y6zXmVHpLjvuRVpMussyChI7bjMKqYtO7LvsYC7sop8vjwVdokM02DEWHy-KUdPJfWEqqJ-oDpqmESIudrPTDdKiF5XGbY7w3g9-YJ-t0TtKKJTZAVuZNk9wiJbF1B6xwen59c3tUatLHxDSzKQ |
linkProvider | Cold Spring Harbor Laboratory Press |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwELbKrhDcWp6lBYwERxdiJ3FyQAhKV1varqo-UG-pH5MqhyZLdlvYn9E_0t_YmTyWE9x6i2R7HI0_z4zteTD23lOdDeVyITVd3cQKRGpAC-cRPCq3NvUUjXwwicen4Y-z6GyF3faxMORW2cvERlD7ytEd-UdKs0KFkkP9ZfpLUNUoel3tS2i0sNiDxW88ss0-737H9f0g5WjnZHssuqoCwqJ608InoBKPmiqPVY7SGUJpvUE7Jc9tkIILfOxNGIFJotSGOgFpXGRz5RxCW7lAId0HbBgqPMoM2PDbzuTwaHmrI1NUj03qZxmnKGrkp6h7SkXo00WDxK8tqbeigCI80ei2RVX_Ka7_beA2im60yoaHZgr1GluB8gl72FaqXDxlNyMnLszlpeEoIWGKB3XRl8-dc1ycwlZ-wVvnkKrmpC0bQHNTAw4hd2PwHA1kfm0cveXzLkEEduLmwhRopfLeMazkdtEQRXAXDkfgJinnM17l_Pjr0bHYrn4K-Yyd3gvfn7NBWZXwknETK2U0KMAmhJdOIiScpy6xXidGxevsXcfWbNrm7MiI9XjayaTOWtavs82e4Vm3bWfZX5AhiWUzbjh6RTElVFfUBy3kABU_TvOiXajlLCoOm1DlV_8n_pY9Gp8c7Gf7u5O9DfaY_o3CG2WyyQbz-gpeo50zt286cHF2ft94vgOT3hDv |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1LT9wwELYKqIgbtOXR0tZIvToidhInxwqI6AuhUqq9RX6MUS7JKiyo-yP4Nf0f_CZmkuyKA0jcIo0f0fizZ-x5MfbFU50N5YKQmp5uMgWiMKCF8wgeFawtPEUj_zrLTi-T75N08igWhtwqbd12_-rb3o5PDtt4-g6b-zCmu7rEr0jqKI0pSDKiZ-po6sMKW6NkZ4TschIt31lkgQJLJ6NB88khUPUdp3xezezFTbnJ1s7NFLot9gqaN-z1UC9y_pbdle7-P8czCqZ4VRaLArYzjuypbevnfHDPaDtO8qqHFDcdYBdy-AXPUUXlt8aRNZ2PKRqwETdXpkY9kS9csxpu5_2gCK_aYQ-EaTO75m3gF19_X4ij9q-Q79hlefLn6FSM9RSERcGuhc9B5R5ldMhUQLkEibTeoIYWgo0LcLHPvElSMHla2ETnII1LbVDO4aZWLlbbbLVpG9hl3GRKGQ0KkIQLrPMUBw6Fy63XuVHZHjsYWVpNh6wZFbEd7xuV1NXA9j22v2B2NW6c64qy6VA97ATJB0syQp7sGKaB9obaoI4ao-jFaXaGRVrOorKkDxZ-_4If-MzWz4_L6ue3sx8f2AaRKchQ5vtsddbdwEfUNmb2Uw-nB5KN0PI |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Fc%CE%B3+receptor-dependent+antibody+effector+functions+are+required+for+vaccine+protection+against+infection+by+antigenic+variants+of+SARS-CoV-2&rft.jtitle=bioRxiv&rft.au=Mackin%2C+Samantha+R&rft.au=Desai%2C+Pritesh&rft.au=Whitener%2C+Bradley+M&rft.au=Karl%2C+Courtney+E&rft.date=2022-11-28&rft.issn=2692-8205&rft.eissn=2692-8205&rft_id=info:doi/10.1101%2F2022.11.27.518117&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2692-8205&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2692-8205&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2692-8205&client=summon |